Well, this is interesting!
Ok so migraine response expected BUT:
Response from tinnitus to anti-CGRP drug!
I’m tempted to pursue this as tinnitus is my one remaining issue.
Very interested to hear from anyone whose tinnitus changed in response to this family of medication !
Short AI Video Summary
A young woman diagnosed with vestibular migraine experienced significant relief of symptoms, including migraines and associated dizziness, after switching to galcanezumab, a CGRP antibody. While she still faces mild tinnitus before her next dose, the patient’s positive response suggests the potential effectiveness of CGRP antibodies in managing complex symptoms of vestibular migraine and tinnitus.
Long AI Video Summary
A young lady previously diagnosed with vestibular migraine had undergone several unsuccessful medical treatments, including nortriptyline, topiramate, diltiazem, and xenismide. Due to these failures, she was shifted to galcanezumab, a CGRP antibody, which targets the CGRP ligand. The patient reported a significant improvement after taking galcanezumab for five months. She no longer experiences migraines or associated dizziness symptoms, with the only remaining issue being tinnitus in the days leading up to her next dose of the antibody. However, she has not experienced any major side effects from the treatment.
The patient experiences tinnitus in both ears, with the left ear being more affected. Despite having normal hearing, she continues to experience tinnitus without any ear fullness. Interestingly, the tinnitus subsides when she receives the next dose of the CGRP antibody before gradually returning towards the end of the dosing cycle. This unique response suggests a potential link between tinnitus and migraine activity, highlighting the effectiveness of CGRP antibodies in treating vestibular migraine and tinnitus symptoms.
The association between treatable tinnitus and migraine activities is significant, given the patient’s positive response to CGRP antibodies. This response is particularly noteworthy as it pertains to the relief of vestibular migraine symptoms and tinnitus, which has not been widely reported previously. The patient’s experience provides valuable insights into the potential efficacy of CGRP antibodies in managing complex symptoms associated with vestibular migraine and tinnitus, offering hope for those who have not responded to traditional treatment methods.
The promising results seen in this case underscore the importance of exploring alternative treatment options for vestibular migraine and associated symptoms such as tinnitus. While the patient still encounters mild tinnitus before the next dose of the antibody, the overall improvement in her condition after switching to galcanezumab highlights the potential of CGRP antibodies in addressing complex migraine manifestations. Further research and clinical trials may be warranted to validate these findings and potentially expand the use of CGRP antibodies in managing vestibular migraine and tinnitus more broadly.
The patient’s willingness to share her experience provides valuable insights into the management of vestibular migraine and tinnitus, shedding light on the potential benefits of CGRP antibodies in addressing these challenging conditions. This follow-up interview showcases the positive impact of personalized medicine and targeted therapies in improving patient outcomes, especially for individuals who have not responded to conventional treatment approaches. Moving forward, continued monitoring and research in this area could pave the way for more effective treatments for vestibular migraine and associated symptoms like tinnitus.